- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
On 27 March 2018, the European Commission withdrew the marketing authorisation for Zinbryta (daclizumab beta) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Biogen Idec Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product.
Zinbryta was granted marketing authorisation in the EU on 1 July 2016 for the treatment of relapsing forms of multiple sclerosis.
The European Public Assessment Report (EPAR) for Zinbryta is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.
Zinbryta : EPAR - Summary for the public
English (EN) (539.87 KB - PDF)
български (BG) (623.68 KB - PDF)
español (ES) (541.35 KB - PDF)
čeština (CS) (551.54 KB - PDF)
dansk (DA) (510.69 KB - PDF)
Deutsch (DE) (543.23 KB - PDF)
eesti keel (ET) (536.52 KB - PDF)
ελληνικά (EL) (628.44 KB - PDF)
français (FR) (542.84 KB - PDF)
hrvatski (HR) (559.5 KB - PDF)
italiano (IT) (536.25 KB - PDF)
latviešu valoda (LV) (588.49 KB - PDF)
lietuvių kalba (LT) (563.73 KB - PDF)
magyar (HU) (598.14 KB - PDF)
Malti (MT) (591.98 KB - PDF)
Nederlands (NL) (541.57 KB - PDF)
polski (PL) (606.49 KB - PDF)
português (PT) (541.48 KB - PDF)
română (RO) (565.84 KB - PDF)
slovenčina (SK) (588.64 KB - PDF)
slovenščina (SL) (582.09 KB - PDF)
Suomi (FI) (536.58 KB - PDF)
svenska (SV) (537.64 KB - PDF)
Product information
Zinbryta : EPAR - Product Information
English (EN) (1.27 MB - PDF)
български (BG) (2.25 MB - PDF)
español (ES) (1.32 MB - PDF)
čeština (CS) (2.16 MB - PDF)
dansk (DA) (1.31 MB - PDF)
Deutsch (DE) (1.41 MB - PDF)
eesti keel (ET) (1.23 MB - PDF)
ελληνικά (EL) (2.63 MB - PDF)
français (FR) (1.33 MB - PDF)
hrvatski (HR) (2.81 MB - PDF)
íslenska (IS) (1.08 MB - PDF)
italiano (IT) (1.09 MB - PDF)
latviešu valoda (LV) (1.88 MB - PDF)
lietuvių kalba (LT) (1.16 MB - PDF)
magyar (HU) (1.88 MB - PDF)
Malti (MT) (1.91 MB - PDF)
Nederlands (NL) (1.07 MB - PDF)
norsk (NO) (1.11 MB - PDF)
polski (PL) (1.87 MB - PDF)
português (PT) (1.09 MB - PDF)
română (RO) (1.22 MB - PDF)
slovenčina (SK) (1.86 MB - PDF)
slovenščina (SL) (1.88 MB - PDF)
Suomi (FI) (1.33 MB - PDF)
svenska (SV) (1.08 MB - PDF)
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Zinbryta : EPAR - All Authorised presentations
English (EN) (477.64 KB - PDF)
български (BG) (517.25 KB - PDF)
español (ES) (481.09 KB - PDF)
čeština (CS) (488.17 KB - PDF)
dansk (DA) (459.95 KB - PDF)
Deutsch (DE) (479.68 KB - PDF)
eesti keel (ET) (483.13 KB - PDF)
ελληνικά (EL) (518.75 KB - PDF)
français (FR) (493.52 KB - PDF)
hrvatski (HR) (488.31 KB - PDF)
íslenska (IS) (481.38 KB - PDF)
italiano (IT) (481.24 KB - PDF)
latviešu valoda (LV) (511.88 KB - PDF)
lietuvių kalba (LT) (498.05 KB - PDF)
magyar (HU) (510.29 KB - PDF)
Malti (MT) (511.19 KB - PDF)
Nederlands (NL) (480.33 KB - PDF)
norsk (NO) (487.39 KB - PDF)
polski (PL) (525.13 KB - PDF)
português (PT) (480.86 KB - PDF)
română (RO) (498.61 KB - PDF)
slovenčina (SK) (508.81 KB - PDF)
slovenščina (SL) (37.55 KB - PDF)
Suomi (FI) (480.09 KB - PDF)
svenska (SV) (17.62 KB - PDF)
Product details
- Name of medicine
- Zinbryta
- Active substance
- daclizumab
- International non-proprietary name (INN) or common name
- daclizumab
- Therapeutic area (MeSH)
- Multiple Sclerosis
- Anatomical therapeutic chemical (ATC) code
- L04AC01
Pharmacotherapeutic group
ImmunosuppressantsTherapeutic indication
Zinbryta is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis (RMS).
Authorisation details
- EMA product number
- EMEA/H/C/003862
- Marketing authorisation holder
- Biogen Idec Ltd
Innovation House
70 Norden Road
Maidenhead
Berkshire SL6 4AY
United Kingdom - Opinion adopted
- 31/03/2016
- Marketing authorisation issued
- 01/07/2016
- Withdrawal of marketing authorisation
- 27/03/2018
- Revision
- 8
Assessment history
Zinbryta Article-20 referral - PRAC assessment report
English (EN) (241.57 KB - PDF)
Zinbryta Article-20 referral - PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage
English (EN) (193.2 KB - PDF)
Zinbryta : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (567.72 KB - PDF)
Zinbryta : EPAR - Scientific Conclusion
English (EN) (518.34 KB - PDF)
Zinbryta-H-A20-1456-C-3862-0010 : EPAR - Assessment Report - Article 20
English (EN) (847.17 KB - PDF)
News on Zinbryta
More information on Zinbryta
Clinical data (initial marketing authorisation)